Why the study?
Conventional triglyceride-lowering therapies have limited efficacy in reducing triglycerides, pancreatitis, or ASCVD in severe hypertriglyceridemia, and the role of novel APOC3 inhibition in ASCVD prevention remains unproven.
Do APOC3-targeted RNA therapies (volanesorsen, olezarsen, and plozasiran) reduce triglyceride levels, acute pancreatitis incidence, and ASCVD risk in patients with familial chylomicronemia syndrome and hypertriglyceridemia?
Do APOC3-targeted RNA therapies (volanesorsen, olezarsen, and plozasiran) reduce triglyceride levels, acute pancreatitis incidence, and ASCVD risk in patients with familial chylomicronemia syndrome and hypertriglyceridemia?
APOC3-targeted RNA therapies (volanesorsen, olezarsen, and plozasiran) robustly lower triglycerides and reduce the risk of acute pancreatitis in familial chylomicronemia syndrome and severe hypertriglyceridemia, though their efficacy in preventing ASCVD events remains to be proven.
Answers are grounded in this paper and cite their sources.
Supports pancreatitis prevention in FCS; leaves open ASCVD prevention pending dedicated trials.
Conventional triglyceride-lowering therapies, such as fibrates and omega-3 fatty acids, have limited efficacy in reducing triglycerides and in reducing the risk of pancreatitis or ASCVD in patients with severe hypertriglyceridemia. ApoC-III inhibits lipoprotein lipase and impairs clearance of both triglyceride-rich and cholesterol-rich lipoproteins. Novel therapies targeting APOC3 mRNA to reduce triglycerides, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), achieve greater triglyceride reductions than standard agents. Volanesorsen and olezarsen, both ASOs, are approved as an adjunct to diet to reduce triglycerides in familial chylomicronemia syndrome (FCS) in different regions. Plozasiran, an siRNA, is in late-stage clinical development. Indirect cross-trial comparisons were performed, aligned by timepoint and outcome measures, and indicate comparable efficacy of olezarsen and plozasiran in patients with chylomicronemia. APOC3 inhibition is now an established therapeutic approach for reducing the risk of acute pancreatitis in FCS, with three agents, volanesorsen, olezarsen, and plozasiran, demonstrating efficacy. However, its role in ASCVD prevention remains unproven. This review evaluates current APOC3 - targeted therapies for FCS, including available comparative data, and synthesizes the emerging literature on the potential of APOC3 inhibition to reduce the burden of acute pancreatitis in broader populations with severe hypertriglyceridemia, as well as its potential role in ASCVD risk reduction.
No takes yet. Share an insight, caveat, or question.
Sotirios Tsimikas (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: